Ketamine and Spravato: The Fastest Path Out of the Darkness of Depression By

Ketamine and Spravato: The Fastest Path Out of the Darkness of Depression

By Mark G. Agresti, MD | Board-Certified Integrative Psychiatrist | DrMarkAgresti.com

Depression is not simply sadness. It is a biological emergency — a neurological storm that robs people of their will to live, their ability to function, and in the most severe cases, their life itself. For decades, psychiatry offered the same limited toolkit: antidepressants that take four to six weeks to work, psychotherapy that requires months of consistent effort, and hospitalization that addresses safety but rarely treats the underlying neurobiology with any meaningful speed.

Then came ketamine — and its FDA-approved nasal spray formulation, esketamine (Spravato) — and everything changed.

At DrMarkAgresti.com, serving Palm Beach and patients across Florida via telemedicine, we understand that for some patients, waiting six weeks for a medication to work is not an option. Ketamine-based treatments offer something psychiatry had never before possessed: rapid, measurable relief from severe depression — often within hours.

This article explores the science, the pharmacokinetics, the neurobiology, and the real-world clinical experience of ketamine and Spravato in treating treatment-resistant and acute depression.

A Crisis in the Emergency Room: When Depression Becomes a Medical Emergency

To understand why ketamine matters so profoundly, consider a scenario that emergency physicians, nurses, and psychiatric consultants see repeatedly every week across America.

A 28-year-old presents to a Palm Beach-area emergency room after being found by a family member in an unresponsive state following an intentional overdose. He is medically stabilized. The toxicology screen clears. The internist signs off. Now comes the hardest part: the psychiatric hold.

He sits in a bare room, on suicide precautions, with no phone, no belongings, and a level of despair that goes beyond words. The on-call psychiatrist assesses him: profound psychomotor retardation, passive suicidal ideation with no future orientation, anhedonia so complete that he describes feeling “already dead.” He has been on two different SSRIs over the past year, both of which failed. A trial of an SNRI produced side effects that caused him to discontinue it. He is what the field calls treatment-resistant.

In the traditional psychiatric model, the options are limited: adjust medications, initiate an inpatient stay, wait. But waiting — in that room, in that state — is itself dangerous. The despair of being held in an emergency room with no perceptible relief is a well-documented risk factor for worsening suicidality.

This is precisely where ketamine changes the clinical equation. In centers where intravenous ketamine or Spravato is available in medically supervised emergency or acute psychiatric settings, a single administration can produce meaningful, observable relief within two to four hours. Not weeks. Hours.

The research literature supports this with striking consistency: studies have shown that a single subanesthetic dose of IV ketamine (0.5 mg/kg over 40 minutes) produces rapid and significant reductions in suicidal ideation in acutely suicidal patients, with effects measurable within 40 minutes of infusion and sustained for 24 to 72 hours. For a patient at acute risk, those hours can mean everything.

What Is Ketamine? A Brief History and Clinical Overview

Ketamine was first synthesized in 1962 by Calvin Stevens at Parke-Davis pharmaceutical laboratories. It was developed as a dissociative anesthetic and entered clinical use in the 1970s, gaining particular prominence in emergency medicine and field surgery due to its ability to induce anesthesia while maintaining airway reflexes and hemodynamic stability. It has been on the World Health Organization’s List of Essential Medicines for decades.

Ketamine exists as a racemic mixture of two mirror-image molecules: R-ketamine and S-ketamine (esketamine). It is the S-enantiomer — esketamine — that has been isolated and FDA-approved as Spravato (esketamine hydrochloride) intranasal spray, specifically for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior (MDSI).

The psychiatric use of ketamine emerged from a landmark 2000 study by Berman and colleagues, who found that a single IV dose produced rapid antidepressant effects in patients with treatment-resistant depression. This finding was replicated by Carlos Zarate and colleagues at the NIMH in 2006 in what became one of the most cited studies in psychiatric pharmacology. The field has never been the same since.

Pharmacokinetics: How Ketamine Moves Through the Body

Understanding ketamine’s pharmacokinetics — how it is absorbed, distributed, metabolized, and eliminated — is essential to appreciating both its therapeutic effects and its clinical administration protocols.

Absorption

Ketamine can be administered via multiple routes. Intravenously (IV), it achieves 100% bioavailability with near-immediate onset. Intranasally — the route used by Spravato — bioavailability is approximately 45 to 50%, a reflection of variable nasal mucosal absorption and first-pass effects. Peak plasma concentrations following intranasal administration are reached within 20 to 40 minutes. Intramuscular administration achieves bioavailability of roughly 93% with onset within 5 to 15 minutes.

Distribution

Ketamine is highly lipophilic — it dissolves readily in fat — which allows it to cross the blood-brain barrier with extraordinary speed. Its volume of distribution is large (approximately 3 L/kg), meaning it distributes extensively into tissues beyond the bloodstream. This rapid CNS penetration is a key reason for its fast onset of action, clinically distinguishing it from virtually every other psychiatric medication in current use.

Metabolism

Ketamine is primarily metabolized in the liver by cytochrome P450 enzymes (CYP3A4 and CYP2B6) through N-demethylation to its primary active metabolite, norketamine. Norketamine retains approximately one-third of ketamine’s anesthetic potency and may play an important role in sustaining antidepressant effects beyond the period of active drug presence. Norketamine is subsequently hydroxylated and conjugated into water-soluble metabolites that are excreted renally.

Emerging research has focused on another metabolite, (2R,6R)-hydroxynorketamine (HNK), which appears to have antidepressant properties independent of NMDA receptor blockade, suggesting that the downstream metabolic cascade of ketamine may be as therapeutically important as the parent molecule itself.

Elimination

The elimination half-life of ketamine is approximately 2 to 4 hours, meaning the drug is largely cleared from systemic circulation within a clinical session. This relatively brief half-life explains why the dissociative and psychotomimetic effects are transient during a treatment session, while the antidepressant effects — mediated through downstream neuroplastic changes — persist well beyond plasma clearance.

The Neuroscience: NMDA Receptor Blockade and the Glutamate Hypothesis of Depression

For most of psychiatric history, depression has been understood primarily through the monoamine hypothesis — the idea that deficiencies in serotonin, norepinephrine, and dopamine underlie depressive illness. SSRIs, SNRIs, and tricyclic antidepressants all operate on this framework. While monoamine-based pharmacotherapy has helped millions of patients, it has clear limitations: slow onset, non-response in a significant minority, and no mechanism that addresses the structural brain changes associated with chronic depression.

Ketamine operates through an entirely different system: the glutamatergic system, which accounts for the vast majority of excitatory neurotransmission in the brain.

The NMDA Receptor

N-methyl-D-aspartate (NMDA) receptors are ionotropic glutamate receptors — ligand-gated ion channels embedded in neuronal cell membranes that play a critical role in synaptic plasticity, memory formation, and learning. Under normal conditions, NMDA receptors are gated by a magnesium ion (Mg2+) that blocks the channel at resting membrane potential. When the neuron is sufficiently depolarized and glutamate binds, this magnesium block is relieved and calcium (Ca2+) and sodium (Na+) ions flow into the cell, triggering intracellular signaling cascades.

Ketamine is an open-channel, non-competitive NMDA receptor antagonist. It enters the ion channel when it is open — typically during periods of neuronal activity — and physically blocks the channel pore. This prevents calcium influx and interrupts the downstream glutamatergic signaling cascade. Ketamine’s binding site is within the channel itself (the PCP site), which is why it is called an open-channel blocker.

Why Blocking NMDA Receptors Treats Depression

The mechanistic bridge between NMDA blockade and antidepressant effect is elegant and counterintuitive. Here is the current model:

Chronic stress and depression are associated with dysregulated glutamate signaling — particularly excessive NMDA receptor activation in the prefrontal cortex and hippocampus. This hyperactivation contributes to excitotoxic damage, synaptic pruning, and the loss of dendritic spines (the physical structures that form synaptic connections).

When ketamine blocks NMDA receptors, it paradoxically triggers a burst of glutamate release through a disinhibition mechanism. This glutamate surge activates a different class of glutamate receptor — the AMPA receptor — which initiates a cascade of intracellular events including activation of BDNF (brain-derived neurotrophic factor) and its receptor TrkB.

BDNF is sometimes called “fertilizer for the brain.” It promotes neuronal survival, growth, and differentiation. The downstream signaling through TrkB activates the mTOR pathway (mechanistic target of rapamycin), which is a master regulator of protein synthesis and, critically, synaptogenesis — the formation of new synaptic connections.

Neuroplasticity: Ketamine Rebuilds the Depressed Brain

The neuroplasticity effects of ketamine are perhaps its most transformative and scientifically remarkable properties — and they represent a fundamental departure from every prior antidepressant mechanism.

Depression is not merely a chemical imbalance. Neuroimaging studies consistently show that chronic depression is associated with measurable structural changes in the brain: reduced gray matter volume in the prefrontal cortex and hippocampus, loss of dendritic spines, reduced synaptic density, and impaired long-term potentiation (LTP) — the cellular basis of learning and memory.

Traditional antidepressants, taken daily for months, can gradually reverse some of these structural changes — but slowly, and incompletely. Ketamine’s mTOR-mediated synaptogenesis works within hours. Preclinical studies using two-photon microscopy have shown that a single ketamine dose in animal models produces measurable increases in dendritic spine density in the prefrontal cortex within 24 hours of administration. These new spines represent new synaptic connections — a literal rebuilding of the neural circuitry that chronic depression has dismantled.

This is why ketamine is sometimes described as not just treating depression, but repairing the brain. For patients who have been severely depressed for months or years, this neuroplastic reset represents a genuine biological fresh start — one that no prior antidepressant was capable of delivering in such a compressed timeframe.

Researchers including Ronald Duman at Yale have described this mechanism as the “synaptic plasticity hypothesis of antidepressant action,” arguing that the common final pathway of all effective antidepressant treatments — including psychotherapy, ECT, and exercise — is ultimately the restoration of synaptic connectivity in mood-regulating circuits.

How Ketamine Is Administered: Delivery Routes and Clinical Protocols

Ketamine for psychiatric use is administered through several different routes, each with distinct pharmacokinetic profiles, clinical contexts, and regulatory frameworks.

Intravenous (IV) Ketamine Infusion

IV ketamine is the most well-studied form for psychiatric use. The standard antidepressant protocol involves a subanesthetic dose of 0.5 mg/kg administered over 40 minutes, typically given in a series of six infusions over two to three weeks. This protocol is based on the seminal NIMH work and has been replicated extensively. IV ketamine is not FDA-approved for depression (it is approved as an anesthetic), meaning its psychiatric use is off-label — but it is widely used in ketamine clinics across the country.

Intramuscular (IM) Ketamine

IM administration offers a less technically demanding alternative to IV. It is often used in settings where IV access is not preferable. Bioavailability is high (approximately 93%), and onset is rapid, though peak plasma levels are somewhat less predictable than IV. IM ketamine is frequently used in urgent psychiatric settings.

Spravato (Esketamine) Intranasal Spray: FDA-Approved and REMS-Certified

Spravato (esketamine hydrochloride) nasal spray was FDA-approved in March 2019 for treatment-resistant depression (TRD) and in August 2020 for major depressive disorder with acute suicidal ideation or behavior (MDSI). It is the S-enantiomer of ketamine, approximately two to four times more potent than R-ketamine at NMDA receptors.

Spravato is available in 56 mg and 84 mg devices. Each device delivers two sprays (one in each nostril) of 28 mg esketamine, for a total of 56 mg per device. The standard dosing protocol begins at 56 mg per session and can be titrated to 84 mg based on efficacy and tolerability.

Because of its dissociative properties and potential for misuse, Spravato is available only through a Risk Evaluation and Mitigation Strategy (REMS) program. Patients must self-administer the medication under direct supervision in a certified healthcare setting and be monitored for at least two hours after each dose. The drug cannot be dispensed for home use. This clinical oversight requirement ensures safety and distinguishes Spravato from conventional oral antidepressants.

The standard Spravato treatment schedule for TRD is as follows:

Induction Phase (Weeks 1 to 4): Twice weekly dosing

Maintenance Phase I (Weeks 5 to 8): Once weekly dosing

Maintenance Phase II (Week 9 onward): Once weekly or once every two weeks, individualized

Case History: Twelve Sessions of Spravato in a Young Adult with Treatment-Resistant Depression

Note: The following is a composite case history drawn from clinical patterns in the treatment literature. Identifying details are fictional. It is presented for educational purposes.

Patient Presentation

“Daniel” is a 24-year-old graduate student from Palm Beach County who was referred to a Spravato-certified outpatient clinic following his second psychiatric hospitalization in twelve months. His diagnosis: major depressive disorder, recurrent, severe, without psychotic features. His PHQ-9 score at baseline was 22 (severe depression). He had failed adequate trials of sertraline, escitalopram, and venlafaxine — each at appropriate doses for at least eight weeks — and had an inadequate response to augmentation with bupropion.

Daniel described his depression in visceral terms: “It’s like being at the bottom of a pool and watching everyone else walk around on the surface. I can see them. I just can’t get up there.” He was not attending classes, had withdrawn entirely from his social network, had stopped exercising, and was sleeping between 13 and 16 hours per day. He denied active suicidal intent but acknowledged passive ideation — a wish that he simply would not wake up.

Sessions 1 and 2 (Week 1 — Induction): First Contact with Spravato

Daniel was started on 56 mg intranasal esketamine. Prior to administration, vital signs were checked (blood pressure, heart rate, oxygen saturation), and baseline dissociation was assessed. He self-administered the two sprays under nursing supervision and was seated in a monitored reclining chair with access to an eye mask and headphones playing ambient music — standard protocol in most Spravato treatment suites.

Within 15 minutes, Daniel noted a significant perceptual shift: a sense of detachment from his body, mild visual distortion, and what he described as “the depression feeling less loud.” Blood pressure elevation (a predictable adverse effect of esketamine) was monitored and resolved within 90 minutes. He remained in observation for two hours as required by the REMS protocol.

The following day — before his second session — Daniel called the clinic. His voice had changed. He reported waking up for the first time in eight months without the immediate, crushing weight of the depression being the first thing he felt. His PHQ-9, administered at session two, had dropped from 22 to 17. Statistically modest; clinically, a revelation. His dose was titrated to 84 mg for session two.

Sessions 3 through 8 (Weeks 2 through 4 — Continued Induction)

The twice-weekly sessions continued at 84 mg. The trajectory was not linear — Daniel had a difficult session four, during which the dissociative experience felt destabilizing rather than relieving. This is clinically recognized: the psychological set and setting of ketamine administration significantly influence the subjective experience. Supportive counseling was provided, the session pace was adjusted, and session five proceeded more smoothly.

By session six, his PHQ-9 had dropped to 11 — moderate depression, down from severe. He was attending classes sporadically. He had texted a friend for the first time in months. He was not well, but the floor of his depression had risen.

By session eight (the end of the formal induction phase), PHQ-9 was 8 — mild-to-moderate. He described it as follows: “The pool thing — I feel like I’m not at the bottom anymore. Maybe I’m at the midpoint. I can see the surface. That’s new.”

Sessions 9 through 12 (Maintenance Phase I): Consolidation and Integration

Transitioning to once-weekly maintenance dosing, Daniel was also formally enrolled in cognitive behavioral therapy (CBT) with a trauma-informed psychotherapist. The combination of Spravato-induced neuroplasticity — new synaptic connections, re-engaged prefrontal circuitry — and active psychotherapy represents what many clinicians consider the ideal treatment model: the ketamine opens the window of neurological flexibility, and therapy helps shape the new growth.

By session twelve, Daniel’s PHQ-9 was 5 — minimal depression. He had returned to full-time coursework, resumed exercise, and was attending weekly therapy with engagement he described as unprecedented. Passive suicidal ideation had fully resolved. He was sleeping 7 to 8 hours per night.

“I don’t know how else to say it,” he said at his 12th session debrief. “I feel like I got my brain back.”

Daniel’s case illustrates what the clinical literature consistently demonstrates: for patients with treatment-resistant depression, a structured 12-session Spravato protocol, combined with ongoing psychotherapy and medication management, can achieve remission where years of conventional pharmacotherapy had failed.

Safety Profile, Side Effects, and Clinical Considerations

Ketamine and Spravato are not without risks. A thorough psychiatric evaluation is essential before initiating treatment, and ongoing monitoring is required throughout. Key considerations include:

**Dissociative effects:** Expected and transient, typically resolving within 1 to 2 hours. For most patients, the dissociative experience is tolerable and some find it therapeutic. A minority find it distressing.

**Cardiovascular effects:** Transient increases in blood pressure and heart rate. Contraindicated in patients with uncontrolled hypertension or a history of hypertensive crises. Vital signs are monitored throughout the session.

**Nausea and dizziness:** Common, particularly with intranasal administration. Pre-treatment antiemetics are used in some protocols.

**Potential for misuse:** Ketamine has known abuse potential, particularly at recreational doses far exceeding therapeutic levels. The Spravato REMS program exists specifically to address this concern.

**Psychosis risk:** Ketamine is contraindicated in patients with a personal or strong family history of psychosis or schizophrenia spectrum disorders, as it can transiently worsen psychotic symptoms.

An Integrative Approach: Ketamine as Part of a Broader Treatment Architecture

At Mark G. Agresti MD LLC, our approach to depression — including treatment-resistant depression — is never reducible to a single modality. Ketamine and Spravato are powerful tools, but they are most effective when integrated into a comprehensive treatment architecture that includes:

**Comprehensive psychiatric evaluation:** Accurate diagnosis is foundational. Depression presenting with mixed features, bipolar underpinnings, trauma comorbidity, or ADHD requires individualized assessment before any treatment decision.

**Psychotherapy integration:** The neuroplastic window opened by ketamine represents an opportunity for enhanced therapeutic gain. CBT, EMDR, ACT, and psychodynamic approaches can all be meaningfully enhanced by the heightened synaptic flexibility that follows ketamine administration.

**Lifestyle medicine:** Exercise, sleep optimization, nutrition, and social engagement are not adjuncts — they are core neurobiological interventions that work through overlapping mechanisms, including BDNF upregulation.

**Medication management:** Oral antidepressants and mood stabilizers remain important tools and are often continued alongside Spravato protocols, particularly to consolidate gains and reduce the frequency of ketamine maintenance dosing over time.

Is Spravato Right for You? Contact Mark G. Agresti MD LLC

If you or someone you love has been living with depression that has not responded to multiple antidepressants, you are not out of options. Spravato and ketamine-based treatments represent a genuine frontier in psychiatric medicine — one grounded in rigorous neuroscience, supported by FDA approval, and increasingly accessible to patients who qualify.

Mark G. Agresti, MD is a board-certified integrative psychiatrist specializing in young adult psychiatry, treatment-resistant mood disorders, and evidence-based integrative approaches. Located at 44 Cocoanut Row, Suite M202, Palm Beach, Florida, and offering statewide telemedicine services, our practice provides comprehensive, personalized psychiatric care.

Visit DrMarkAgresti.com to learn more or to schedule a consultation.

Practice: Mark G. Agresti MD LLC

Address: 44 Cocoanut Row, Suite M202, Palm Beach, FL 33480

Website: DrMarkAgresti.com

**Medical Disclaimer:** This article is intended for educational and informational purposes only and does not constitute medical advice. Ketamine and Spravato are medical treatments that require evaluation by a qualified physician. Always consult a board-certified psychiatrist before initiating or modifying any psychiatric treatment. If you are experiencing a mental health crisis, please call 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room.

SEO Keywords: